Fusen Pharmaceutical Co (HKSE:01652) Net Income From Continuing Operations : HK$-39.7 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Fusen Pharmaceutical Co's net income from continuing operations for the six months ended in Dec. 2023 was HK$-57.7 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-39.7 Mil.

Fusen Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Fusen Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co Net Income From Continuing Operations Chart

Fusen Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

71.01

92.94

29.13

-34.61

-32.21

Fusen Pharmaceutical Co Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial											-33.30	-8.30	-30.80	17.99	-57.69

Fusen Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-39.7 Mil.

Fusen Pharmaceutical Co (HKSE:01652) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN

Website

http://www.fusenyy.com

Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.

Executives

Cao Changcheng	2201 Interest of corporation controlled by you
Quan Xiufeng	2202 Interest of your spouse
Full Bliss Holdings Limited	2101 Beneficial owner
One Victory Investments Limited	2101 Beneficial owner
Cao Zhiming	2201 Interest of corporation controlled by you
Zhou Peilin	2202 Interest of your spouse
Rayford Global Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
First Joint Elegant Limited	2101 Beneficial owner
Fung Wai Sze	2202 Interest of your spouse
Lam Yiu Por	2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines